Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles by Zhao, Dongmei et al.
© 2010 Zhao et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2010:5 669–677
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
669
OrIgINAL reseArch
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/IJN.S12918
Preparation, characterization, and in vitro targeted 
delivery of folate-decorated paclitaxel-loaded 
bovine serum albumin nanoparticles
Dongmei Zhao
Xiuhua Zhao
Yuangang Zu
Jialei Li
Yu Zhang
ru Jiang
Zhonghua Zhang
Key Laboratory of Forest Plant 
ecology, Northeast Forestry 
University, Ministry of education, 
harbin, heilongjiang, china
correspondence:   Yuangang Zu 
Key Laboratory of Forest Plant  
ecology, Northeast Forestry University, 
Ministry of education, harbin, 
heilongjiang 150040, china 
Tel +86 451 8219 1517 
Fax +86 451 8210 2082 
email zygorl@yahoo.com.cn
Abstract: Paclitaxel (Taxol®) is an important anticancer drug in clinical use for treatment 
of a variety of cancers. Because of its low solubility, it is formulated in high concentration 
in Cremophor EL® which induces hypersensitivity reactions. In this study, targeted delivery 
of paclitaxel-loaded nanoparticles was prepared by a desolvation procedure, crosslinked on 
the wall material of bovine serum albumin, and subsequently decorated by folic acid. The 
characteristics of the nanoparticles, such as amount of folate conjugation, surface morphology, 
drug entrapment efficiency, drug loading efficiency, and release kinetics were investigated 
in vitro. The targeting effect was investigated in vitro by cancer cell uptake of fluorescein 
isothiocyanate-labeled nanoparticles. The spherical nanoparticles obtained were negatively 
charged with a zeta potential of about −30 mV , and characterized around 210 nm with a narrow 
size distribution. Drug entrapment efficiency and drug loading efficiency were approximately 
95.3% and 27.2%, respectively. The amount of folate conjugation was 9.22 µg/mg of bovine 
serum albumin. The folate-decorated nanoparticles targeted a human prostate cancer cell line 
effectively.
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Introduction
Paclitaxel, a major anticancer drug isolated from the bark of Taxus brevifolia, has been 
used in the treatment of a wide variety of cancers. Because of its low solubility, its 
commercial formulation, Taxol®, is formulated in a high concentration in Cremophor 
EL®, which induces hypersensitivity reactions.1 Another limitation of paclitaxel is its 
systemic toxicity, which causes severe adverse effects.2 Many approaches have been 
proposed, including micellar carriers, soluble polymers, paclitaxel-soluble prodrugs, 
and polymeric nanocapsules, in order to improve the therapeutic effects of paclitaxel 
and reduce its side effects.3–5
Drug-loaded nanoparticles with biodegradable carriers have the potential to 
  provide an ideal solution for most of the major problems with anticancer drugs. 
Drug   incorporation into nanoparticles follows a new concept to improve drug 
solubility, with a variety of advantages compared with standard paclitaxel therapy.6,7 
Polymers have been used to develop paclitaxel-loaded nanoparticles, including an 
amphiphilic polymeric micelle of poly 2-(4-vinybenzyloxy0-N,N-diethylnicotinamide) 
(PDENA), PEG PEO-PLGA, cholesterol-grafted poly(N-isopropylacrylamide-co-N, 
N-  dimethylacrylamide-co-undecenoic acid) and poly(ε-caprolactone)/Poloxamer 188 
(PCL/Poloxamer 188).8–11International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Albumin is the most abundant protein in plasma (35–50 g/L 
human serum) with a molecular weight of 66.5 kDa, which 
is stable in the pH range of 4–9, soluble in 40% ethanol, 
and can be heated at 60°C for up to 10 hours without 
deleterious effects. These properties, as well as preferential 
uptake in tumor and inflamed tissue, ready availability, 
biodegradability, and lack of toxicity and immunogenicity 
make serum albumin an ideal candidate for drug delivery. 
Recent applications of serum albumin (human and bovine) 
have demonstrated some advantages as a natural and therefore 
biocompatible and biodegradable carrier for drugs.12–14 The 
albumin-based drug delivery system has increased the disease 
tissue/normal tissue drug concentration ratio. Nanoparticles 
of human serum albumin-bound paclitaxel (Abraxane, an 
example of nabTM [nanometer albumin-bound] technology), 
have been approved by the Food and Drug Administration 
and a Phase III trial of a variety of cancer.15,16 Clinical studies 
have shown that nab-paclitaxel is significantly more effective 
than paclitaxel formulated as Cremophor EL® (CrEL, Taxol®, 
CrEL-paclitaxel), with almost double the response rate and 
increased time to disease progression.17
Specific targeting of tumor cells to achieve higher drug 
levels in tumor tissue and to minimize side effects is the 
major goal in cancer therapy. To achieve active targeting, 
nanoparticles should be equipped with functional mol-
ecules which can recognize and adhere to biomarkers on 
the surface of target cancer cells. Among targeting agents 
directed to membrane-bound tumor-associated receptors, 
folic acid has been widely utilized as a ligand for folate 
receptor-mediated selective targeting and delivery of drugs 
into tumor cells.18 The folate receptor has been found to 
be overexpressed in a wide range of tumors, and is known 
as a high-affinity membrane folate-binding protein, which 
mediates uptake of the vitamin by receptor-mediated endo-
cytosis.19,20 Folate receptors exist in three major forms, ie, 
folate receptor-α, folate receptor-β, and folate receptor-γ. 
The folate receptor-α form may be further qualified as a 
tumor-specific target overexpressed by many types of tumor 
cells, including those of the ovary, brain, kidney, breast, 
myeloid cells, and lung, because it generally becomes acces-
sible to intravenous drugs only after malignant transforma-
tion.19 The role of folate receptors in the cellular transport 
of folate is not well understood, although a potocytosis 
(caveolin-coated endocytosis) model has been proposed.20 
Recently, it has been reported that folate-mediated delivery 
of drug-loaded nanoparticles can enable binding, promote 
uptake, and have increased cytoxicity to cancer cells in 
vitro and in vivo.21–23
In the present study, the surfaces of paclitaxel-loaded 
biodegradable bovine serum albumin nanoparticles (PTX-
BSANPs) were modified by covalent attachment of folate 
to enable tumor cell-targeting ability. Characterization of 
the nanoparticles, including size and zeta potential, was 
carried out. Drug entrapment efficiency, drug loading 
efficiency, and release properties in vitro were also tested. 
The targeting effect of PTX-BSANPs with folate decoration 
(PTX-FA-BSANPs) was investigated in vitro by the uptake of 
fluorescence-labeled nanoparticles in PC3, a human prostate 
cancer cell line.
Materials and methods
Materials
Folic acid, bovine serum albumin, trypsin, phosphate-buffered 
saline (pH 7.4), and fluorescein isothiocyanate were obtained 
from Sigma Aldrich, (St. Louis, MO). The paclitaxel was 
provided by Hisun Pharmaceutical Co. Ltd (Zhejiang, China). 
Ethanol and dichloromethane were used as analytic reagents. 
Methanol and cetonitrile were also used as analytic agents 
and were of high performance liquid chromatography grade. 
The water used was pretreated with the Milli-Q plus system 
(Millipore, Bedford, MA).
Preparation of PTX-BsANPs with folate 
decoration
The PTX-BSANPs were prepared as previously described 
using a desolvation technique.24,25 Bovine serum albumin 
was first dissolved in deionized water, a desolvating reagent. 
Paclitaxel dissolved in ethanol was added using a peristaltic 
pump TI/62/20 (Medorex, Norten-Hardenberg, Germany) 
at room temperature (1 mL/min). Thereafter, 0.25% 
glutaraldehyde solution was added to crosslink the amino 
groups in the nanoparticles. The crosslinking process was 
performed during stirring of the suspension for16 hours. The 
pH of the bovine serum albumin suspension was adjusted 
using 0.1 M carbonate/bicarbonate buffer. The desolvating 
reagent was removed by evaporation using a rotary evapo-
rator R201BL (SENCO, Shanghai, China) at 40°C, and the 
nanoparticles were then redispersed in an ultrasonication 
bath TI-H-5 (Elma, Singen, Germany). The nanoparticles 
were collected by centrifugation at 16,000 g for 15 minutes 
(Sigma 3 K30, Harz, Germany), followed by washing twice 
with ethanol and deionized water. The suspension produced 
was freeze-dried for 48 hours using 5% mannitol as the 
cryoprotectant to obtain a fine powder of nanoparticles.
We used the method for preparing N-hydroxysuccinimide 
ester of folate (NHS-folate) reported by Lee and Low.26 International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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The carboxylic groups of NHS-folate were conjugated with 
the amino groups of the BSANPs under alkaline condi-
tions (pH 10.0). NHS-folate 5 mg was dissolved in 0.1 M 
  carbonate/bicarbonate buffer (pH 10.0, 1.0 mL) and the 
stirred PTX-BSANPs suspension was added. This reaction 
took 12 hours. The unassociated NHS-folate in the mixture 
was then removed by dialyzing it against deionized water 
using Slide-A-Lyzer dialysis cassettes with a molecular 
weight cut-off of 3500 for 48 hours (Pierce, Rockford, 
IL), followed by freeze-drying, and the PTX-FA-BSANPs 
were obtained.
evaluation of folate conjugated  
with PTX-BsANPs
The amount of folate that had been conjugated with the 
PTX-BSANPs was evaluated using the method described by 
Zhang.27 Briefly, after dialysis against deionized water, PTX-
FA-BSANPs (1 mg in 1 mL deionized water) were digested 
by trypsin (0.05 mg/mg bovine serum albumin). The result-
ing tryptic hydrolysis of PTX-FA-BSANPs was scanning 
in the range 250–450 nm by ultraviolet spectrophotometer 
(Shimadzu, Tokyo, Japan) using tryptic hydrolysis of PTX-
BSANPs as a blank control. The extent of folate conjugated was 
determined relative to a folate reference: y = 0.0699 × −0.0385, 
R2 = 0.999 (y: absorption; x: folate concentration, µg/mL).
characterization of PTX-BsANPs  
with folate decoration
Particle size and size distribution
Average particle size and size distribution of the nanoparticles 
were measured by laser light scattering (LLS, Zetaplus; 
Brookhaven Instruments, Holtsville, NY). The nanoparticles 
were diluted with deionized water and sonicated for several 
minutes before measurement.
surface charge
The zeta potential of the PTX-FA-BSANPs was deter-
mined using a Zetaplus zeta potential analyzer (Brookhaven 
Instruments) at room temperature. The samples were prepared 
by diluting the nanoparticle suspension with deionized 
water. The data were obtained from the average of several 
measurements.
surface morphology
The shape and surface morphology of PTX-BSANPs and 
PTX-FA-BSANPs were investigated by scanning electron 
microscopy (SEM, FEI Co., Eindhoven, The Netherlands).
Physical status of paclitaxel and nanoparticles
An X-ray diffractometer (Philips, Xpert-Pro, The   Netherlands) 
was used to determine the physical status of paclitaxel in the 
nanoparticles. The diffraction angle (2θ) was recorded from 
3° to 80° with a scanning speed of 5°/minute. CuKa radiation 
was used as the X-ray source at 40 kV and 30 mA.
Drug encapsulation and loading efficiency
The paclitaxel in ethanol was examined by high performance 
liquid chromatography, ie, a Waters liquid chromatograph 
(Waters Corporation, Milford, MA), consisting of a Waters 600 
Controller equipped with a Waters 717 Plus autosampler, and a 
Waters 2487 UV detector. The samples were chromatographed 
at 25°C by injection of a 10 µL sample into a Diamonsil C18 
column, 250 mm × 4.6 mm × 5 µm (Dikma Technologies, 
Beijing, China). The mobile phase was a mixture of methanol 
and acetonitrile in a volume ratio of 60:40 (v/v). The elution 
rate was 1.0 mL/min and the paclitaxel wavelength was set 
at 227 nm (Supplementary Figure 1). The drug entrapment 
efficiency and drug loading efficiency were calculated using 
previously reported equations:
DEE=
PTXP TX
PTX
(Total)( in supernatant)
(Total)
−
DLE=
PTXP TX
PTX-FA-BSANPs
(Total)( in supernatant) −
Drug release
Paclitaxel release from the nanoparticles was determined in 
phosphate-buffered saline (0.1 M, pH 7.4) at 37°C. PTX-FA-
BSANP suspension (0.5 mg/mL, 2 mL, without mannitol) was 
placed in Slide-A-Lyzer dialysis cassettes (MWCO 3500), and 
then the dialysis cassettes were immersed in a 250 mL beaker 
containing 200 mL release buffer. The beaker was placed in 
an incubator shaker at 37°C and 100 rpm. The release buffer 
(100 mL) was withdrawn from the beaker and replaced with 
100 mL fresh release buffer at regular time intervals. The pacli-
taxel concentration in each collected release buffer sample was 
determined by high performance liquid chromatography.3
Paclitaxel was extracted from the removed medium after 
partitioning into the organic phase. Dichloromethane 6 mL was 
added to the medium, vortexed vigorously for five minutes, and 
left to stand for 15 minutes. Upon phase separation, the denser 
organic dichloromethane layer was carefully drip-separated 
from the aqueous buffer phase and allowed to evaporate at 
room temperature overnight. The dried sample containing International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
672
Zhao et al
paclitaxel was then dissolved in 2 mL of methanol and analyzed 
by high performance liquid chromatography. A profile showing 
cumulative drug release as a function of time was plotted.10 
Each diffusion experiment was repeated in triplicate, and the 
mean values and standard deviations were calculated.
cell culture
Human prostate cancer PC3 cells were cultured in   folate-free 
RPMI 1640 medium containing 10% fetal calf serum and 0.1% 
antibiotics, at 37°C in a 5% CO2 humidified atmosphere.
Fluorescence microscopic images  
of nanoparticles
For qualitative uptake studies, the cells were reseeded in 
six-well transparent plates. Cells were washed three times 
with cold phosphate-buffered saline after incubation with 
fluorescein isothiocyanate-labeled nanoparticles for four 
hours and 12 hours at 37°C. Thereafter, cells were observed 
by confocal laser scanning microscopy (Nikon, Tokyo, Japan) 
with Fluoview imaging software.
Results and discussion
characterization of PTX-BsANPs  
with folate decoration
PTX-BSANPs prepared using the one-step   desolvation   technique 
of ethanol as the desolvating agent and   glutaraldehyde as the 
crosslinking agent have been found to be highly stable in water 
and in cell medium. This method leads to the formation of least 
aggregated particles with a uniform distribution, and bovine 
serum albumin has been used in many studies as a delivery 
agent.23–25 Bovine serum albumin is a protein with an amino 
group and an acid group, so the process of nanoparticles cross-
linking with glutaraldehyde might be affected by the pH of the 
medium. According to a report by Rahimnejad,14 particle size 
might be slightly influenced with a change of pH in the range 
of 170–210 nm. Sixty amino moieties in lysine residues and 26 
arginine moieties in guanidine side chains,28 ie, about 10 percent 
of bovine serum albumin protein with 583 residues, might be 
solidified by a condensation reaction with a reagent   containing 
an aldehyde group. As previously reported by Weber et al24 for 
desolvated human serum albumin particles, the lowest required 
glutaraldehyde concentration for the production of stable nano-
particles appears to be about 40%. In our study, the glutaraldehyde 
concentration required for the production of stable nanoparticles 
was set up to 50%. For the bovine serum albumin protein, about 
90% of free amino residues could maintain protein function.
NHS-folate had three absorption maximum from 250 
to 400 nm, and the absorption peak of digested PTX-FA-
BSANPs at 358 nm confirmed the successful conjugation 
of folate with BSANPs (Figure 1a). Moreover, according to 
the calibration curve of NHS-folate, 9.22 µg NHS-folate was 
conjugated with 1 mg BSANPs.
The X-ray diffraction spectrum of paclitaxel and 
  freeze-dried PTX-FA-BSANPs is shown in Figure 1b. The 
disappearance of the characteristic peak (2θ = 12.4°) of 
paclitaxel in the PTX-FA-BSANPs suggested that paclitaxel 
was in an amorphous or disordered crystalline phase in the 
solid solution.
Average particle size and distribution of the nanoparticles 
were measured by laser light scattering. The PTX-FA-BSANPs 
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had an average size of 217.0 ± 3.6 nm with a polydispersity 
of 0.034 ± 0.004 (Figure 2c). Comparing with PTX-BSANPs 
(202.3 ± 3.9 nm, Figure 2f ), the folate-decorated nanopar-
ticles had the larger size.
Surface charge is an important indication of the   stability 
of a colloidal nanoparticle system in medium. The   repulsion 
among the nanoparticles with the same type of surface 
charge provides extra stability. The zeta potential of the 
  PTX-FA-BSANPs indicated negative charges on the nanopar-
ticle surface (−30.91 ± 1.97 mV), while that of PTX-BSANPs 
was around −25 ± 2.12 mV .
SEM was used to image the morphology of the PTX-
BSANPs and PTX-FA-BSANPs with and without mannitol 
(Figures 2a, 2b, 2d, and 2e). It was revealed by SEM imaging 
that the nanoparticles were generally spherical in shape with 
a narrow size distribution. Figures 2d and 2e show the SEM 
images of nanoparticles freeze-dried with mannitol. Figure 3a 
shows the PTX-FA-BSANPs freeze-dried powder. The PTX-FA-
BSANPs were well dispersed after adding mannitol. Moreover, 
no crystal precipitations were observed in PTX-FA-BSANP 
suspension (Figure 3b), which demonstrates the stability and 
applicability of the obtained drug delivery system.
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Figure 2 characterization of PTX-BsANPs and PTX-FA-BsANPs. scanning electron microscopic images of A) PTX-BsANPs. B) PTX-BsANPs with mannitol. D) PTX- 
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The bovine serum albumin concentration and quantities 
of ethanol and glutaraldehyde required, as well as the correct 
ratio of bovine serum albumin to paclitaxel, were investi-
gated in the early research, ensuring high encapsulation and 
uniform particle size for the present study. The highest drug 
entrapment and loading efficiency achieved were 95.3% 
and 27.2%, respectively. At the loading level, the effective 
concentration of paclitaxel would be 285.6 mg/L, which is 
already 910 times higher than its intrinsic water solubility 
of 0.3 mg/L.
In vitro drug release
The in vitro drug release profiles of the PTX-FA-BSANPs 
over 144 hours are shown in Figure 4. An initial burst of 
26.2% in the first 12 hours can be observed. In the   following 
36 hours, cumulative release reached 46.6%, in a sustained 
manner, which provides the possibility to fight continually 
against cancer cells, resulting in decreased cancer cell 
viability. Cumulative release reached almost 85% after 
seven days and showed an almost released ability of the 
nanoparticle formulation. The in vitro drug release of PTX-
FA-BSANPs corresponded with the Higuichi equation of 
y = −115.39e(−x/202.35) − 24.39e(−x/7.94) + 139.09 (R2 = 99.9). 
The generally sustained and controlled release profile of 
paclitaxel facilitates the application of nanoparticles for the 
delivery of anticancer drugs.
The crosslinking process with glutaraldehyde plays 
a major role in the stability and drug release from the 
  desolvated BSANPs.29 Compared with the slow release 
of paclitaxel,30 the continuous release of paclitaxel from 
the PTX-FA-BSANP solution scan be attributed to the 
solubilizing ability of the bovine serum albumin carrier. 
The erosion and degradation of BSANPs and the insolubil-
ity of paclitaxel in water were involved in the drug-release 
process.
In vitro cellular uptake
It has been demonstrated that the therapeutic effects of drug-
loaded nanoparticles depend on internalization and sustained 
retention of the nanoparticles by diseased cells.31 Although 
the in vitro and in vivo biologic processes could be very dif-
ferent, an in vitro investigation may provide some   preliminary 
evidence to show the advantages of nanoparticles. Fluores-
cein isothiocyanate, a fluorescence marker, has been widely 
used as a probe for marking nanoparticles in cellular uptake 
experiments.21,31 The cellular uptake of PTX-BSANPs and 
PTX-FA-BSANPs labeled by fluorescein isothiocyanate was 
examined to demonstrate internalization of the nanoparticles 
into cells and the targeting effects. Internalization of the 
nanoparticles was visualized by confocal laser scanning 
microscopy. In Figures 5b, 5c, and 5d, the fluorescence from 
the nanoparticles internalized in cells is shown. Figures 5b 
and 5c show the images of the cells incubated for four hours 
with PTX-BSANPs and PTX-FA-BSANPs. A significant 
fluorescence difference between PTX-BSANPs and PTX-
FA-BSANPs can be observed. The PTX-FA-BSANPs were 
detected by the higher target effect. The results show that 
the folate-conjugated nanoparticles had better target deliv-
ery than nanoparticles without folate conjugation. When 
incubated for 12 hours with PTX-FA-BSANPs, the cells had 
been almost saturated by the fluorescence (Figure 5D). It is 
concluded that targeting of folate-decorated nanoparticles is 
significant and effective.
High-affinity folate-binding protein was character-
ized in the human prostate cancer cell line, and folic acid 
binds to the membrane fraction that crossreacts with the 
  antiprostate-specific membrane antigen antibody.32 In 
PC-3 cells, folate receptor and antiprostate-specific mem-
brane antigen mRNAs were not often observed by real-time 
polymerase chain reaction, while reduced folate carrier 
mRNA was present.33 An fluorescein isothiocyanate-labeled 
folate-bovine serum albumin conjugate was taken up by the 
prostate cancer cells, and the cellular association was signifi-
cantly decreased in the presence of 1 mM folic acid.33 This 
result confirms the target effect detected in human prostate 
cancer cells in the study.
One important difference between bovine and human 
serum albumin is that bovine albumin has two tryptophan 
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Figure 4 In vitro paclitaxel release profile from PTX-FA-BSANPs.   Phosphate-buffered 
saline (0.1 M, ph = 7.4) was selected as the release medium. The nanoparticle dispersion 
was put in an orbital shaker and shaken at 120 rpm at 37°c. high performance liquid 
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residues while human albumin has a unique tryptophan, 
although they have a similar folding, a well known primary 
structure. The PTX-BSANPs prepared in this study had a 
similar function to human serum albumin-bound paclitaxel 
prepared by high-pressure homogenization, and were also 
detected in similar target lesion as that of human serum 
albumin-bound paclitaxel. Two transport pathways for 
human serum albumin-bound paclitaxel has been proposed. 
Albumin paclitaxel molecules bind to an albumin receptor 
(gp60), which cluster on endothelial surfaces and associates 
with caveolin-1, which transports the hydrophobic paclitaxel 
into the extravascular space.34,35 A second proposed transport 
pathway for the nanoparticle is via secreted protein acidic 
and rich in cysteine (SPARC). SPARC protein can bind 
albumin and can increase the concentration of the albumin-
bound paclitaxel particle in the tumor due to such binding.6 
The transport mechanism of human serum albumin-bound 
paclitaxel could be used to explain the target effect of PTX-
BSANPs detected in our study.
Conclusion
In this study, nanoparticles of folate-conjugated water-
insoluble paclitaxel-loaded bovine serum albumin have been 
successfully synthesized and characterized by a desolvation 
technique. The nanoparticles showed natural property, high 
stability, desired surface properties in favor of cellular uptake 
and can be targeted specifically to cancer cells. The water 
solubility of paclitaxel increased significantly. It should be 
pointed out that this is only a proof-of-concept investigation. 
Bovine serum albumin would be substituted by human 
serum albumin in further experiments in order to avoid a 
possible immunologic response in vivo. In vitro cytosis and 
in vivo investigation should now be undertaken to collect 
sufficient data for the clinical application of paclitaxel-loaded 
nanoparticles.
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Figure S1 Chromatograph profile of paclitaxel by high performance liquid chromatography.